Stay updated on Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.

Latest updates to the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedMajor update adds a government operations notice and NIH Clinical Center status with a v3.2.0 release; removes a specific resource (Small cell lung carcinoma) from the GARD list and drops the v3.1.0 reference.SummaryDifference2%

- Check27 days agoChange DetectedUpdated the page version from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.0%

- Check42 days agoChange DetectedUpdated from v3.0.1 to v3.0.2, indicating a new patch release; the Back to Top link was removed as a minor UI change. No other substantive changes to core content were detected.SummaryDifference0.1%

- Check49 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1%

- Check56 days agoChange DetectedThe web page has updated its facility name and location details, specifically highlighting Washington D.C. and the addition of various medical terms related to proteins and antibodies, while removing some previous location and cancer-related topics.SummaryDifference2%

- Check70 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.0%

Stay in the know with updates to Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.